Format

Send to

Choose Destination
Kidney Dis (Basel). 2017 Jul;3(1):8-14. doi: 10.1159/000477244. Epub 2017 Jun 16.

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.

Hocher B1,2,3,4, Pasch A5.

Author information

1
Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany.
2
IFLb, Institut für Labormedizin Berlin, Berlin, Germany.
3
Department of Embryology, Medical School of Jinan University, Guangzhou, China.
4
Department of Nephrology, Guangzhou Overseas Chinese Hospital, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
5
Department of Clinical Research, University Hospital Bern, University of Bern, Bern, Switzerland.

Abstract

BACKGROUND:

Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients.

SUMMARY:

In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified.

KEY MESSAGE:

There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome.

KEYWORDS:

Biomarker; Calcification propensity; Chronic kidney disease-mineral and bone disorder; Morbidity; Mortality; Nonoxidized parathyroid hormone; T50 test

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center